DERMAVANT SCIENCES

A leader in the development of new potential treatments in medical dermatology.

AD affects 10-20% of children and up to 3% of adults. It is an inflammatory disease characterized by intensely itchy rashes that negatively impact patients’ quality of life. Dermavant is developing targeted topical therapies for patients with all severity levels of AD.